Bristol Myers Squibb (BMY): Kewajiban utang agregat

Bristol-Myers Squibb (BMY) dominates the oncology segment through its patents, utilizing a robust cold chain system for global supplies. Total debt levels on this chart demonstrate financial stability, with the metric value standing at 47.72. However, the loss of exclusivity for legacy drugs and the slow rollout of new products are temporarily increasing the company's operating expenses.

BMY BMS: Gunggung utang perusahaan ing interval 04.07.2022 - 31.10.2026

Rincian analitis perusahaan Bristol Myers Squibb (BMY)

- nilai saham lan prakiraan konsensus rega:

Rega saham Bristol-Myers Squibb Co.|BMY - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar BMS|BMY - Nilai Total Perusahaan

- indikator kapitalisasi buku:

Nilai Akuntansi saben Saham Bristol Myers Squibb|BMY - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku bms.com|BMY - Gunggung Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Rasio Kabeh Utang marang Dana Pribadi Bristol-Myers Squibb|BMY - Utang jangka dawa marang modal|Rasio tanggungan utang jangka cendhak marang modal Bristol Myers Squibb Company|BMY - Utang perusahaan|Utang-utang marang nilai buku BMS|BMY - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Bristol Myers Squibb|Rasio likuiditas darurat bms.com

- data bathi bisnis lan rasio investasi:

BMY - Bathi resik

Analisis fundamental perusahaan:BMY - Bristol-Myers Squibb Co.

Produk dadi Bristol Myers Squibb Company

Total credit obligations reflect the overall volume of borrowed capital subject to repayment. By analyzing the debt change chart, an investor assesses the issuer's solvency. This metric aggregates all long-term and short-term liabilities, determining the degree of financial leverage. For Bristol-Myers Squibb (BMY), this balance is critical as the company prepares for the loss of patent protection on key drugs. Debt control allows the behemoth to maintain its investment status in oncology.

Pesaing Bristol-Myers Squibb